Pemphigus is a group of autoimmune diseases characterized by the formation of erosions and/or flaccid bullae of the skin and/or mucosae. The definition "drug-induced pemphigus" has been coined to indicate cases of pemphigus with clinical, histological and immunopathologic features similar to those of the idiopathic disease but induced by systemic ingestion or local use of some drugs. The present authors analyzed a case series of three case reports with clinical and pharmacological features compatible with the diagnosis of angiotensin converting enzyme inhibitors or angiotensin II receptor blocker drug-induced pemphigus. The patients were visited by the dermatological Unit of Magna Graecia University in Catanzaro. All suspected drug induced pemphigus were treated by suspending the suspected drug and by starting a treatment with systemic corticosteroid drugs, leading to a remission of the clinical manifestations in some months.
| INTRODUCTION
Pemphigus is a group of autoimmune diseases characterized by the formation of erosions and/or flaccid bullae of the skin and/or mucosae. It is a chronic and potentially lethal dermatosis with an estimated incidence of 1/150,000 (an annual incidence of 1/150,000 in the United Kingdom). Its severity is based on its progressive course which is accompanied by an increased body catabolism with loss of body fluids and proteins, and secondary bacterial and viral infections which may lead to sepsis and cardiac failure. Before the advent of systemic corticosteroids, the prognosis of pemphigus was almost always fatal (Langan et al., 2008) . All forms of pemphigus are characterized by the development of autoantibodies to the desmosomal proteins, which can be found in many areas of the body, but which play a major role in the epidermal layers. Pemphigus vulgaris (PV) and pemphigus foliaceous (PF) are caused primarily by antibodies to Desmoglein 1 (Dsg 1) in PF, Desmoglein 3 (Dsg 3) in mucosal dominant PV, or both in mucocutaneous PV (Tavakolpour & Tavakolpour, 2016) . Dsg 1 and 3 are found in varying amounts in the epidermis of the skin and mucosa.
Dsg 1 is found in higher amounts in the upper layers of the epidermis, especially on the skin, whereas, Dsg 3 is found in the lower layers of the epidermis with higher concentrations in the mucosa and skin (Giordano & Sinha, 2012; Kitajima, 2003; Ohzono et al., 2015; Ruocco et al., 2016) . The disease usually occurs in patients with certain Human leukocyte antigen (HLA) genotypes generating B-cells responsible for the specific autoantibodies. The activation of these B-cells requires a complex interaction with CD4+ T helper 2 (Th2) cells and the Th2 cells' over-activation leads to the autoantibody production which is necessary for PV and PF (Giordano & Sinha, 2012; Ruocco et al., 2016; Tavakolpour & Tavakolpour, 2016) . The production of autoantibodies and epitope binding is sufficient to cause loss of adhesions between desmosomes leading to separation of keratinocytes which is directly related to disease activity. Tumor necrosis factor-α, IL-1, and other cytokines also play a smaller role in the pathogenesis of pemphigus (Ruocco et al., 2016) . Paraneoplastic pemphigus (PNP) is a unique from PV and PF in that it may contain autoimmune antibodies to Desmoglein 1 and 3 but has more specific antibodies to envoplakin and periplakin (Lo Schiavo et al., 2013) . Although envoplakin and periplakin are the most specific for PNP, patients with this disease can develop multiple autoantibodies primarily to desmosomal proteins, including the plakin family of proteins (plectin, BP230, and desmoplakin), desmocollins, and alpha-2-macroglobubin-like antigen-1 (Poot, Siland, Jonkman, Pas, & Diercks, 2016) . Based on clinical presentation, histologic and immunopathological characteristics, pemphigus can be classified into nine types (Table 1) : Pemphigus vulgaris, pemphigus vegetans, pemphigus erythematosus, pemphigus foliaceus, endemic pemphigus foliaceus, penfigus erpetiformis, paraneoplastic pemphigus, drug-induced pemphigus, and IgA pemphigus. Table 1 modified from Kitajima (2003) .
The definition "drug-induced pemphigus" has been coined to indicate cases of pemphigus with clinical, histological and immunopathologic features similar to those of the idiopathic disease but induced by systemic ingestion or local use of some drugs (Brenner & Goldberg, 2011) . It is hypothesized, that in patients with an underlying genetic predisposition, some drugs can act by either modifying the immune response or altering the antigenic properties of the epidermal basement membrane.
In particular, it seems that drugs might induce the production of anti-cutaneous basement membrane zone antibody by acting as haptens able to bind the proteins in the lamina lucida and change their antigenic properties, or stimulating an autoimmune response through structural change and discovering hidden epitopes (Ruocco & Sacerdoti, 1991 , Mutasim, Pelc, & Anhalt, 1993 , Ruocco, De Angelis, & Lombardi, 1993 , Wolf, Tamir, & Brenner, 1991 , Ong, Cook, & Lee, 2000 .
The drugs suspected of inducing pemphigus are:
1. Thiols or mercaptans (containing a sulfhydryl group).
2. Phenolic drugs.
3. Drugs with an active amide group.
4. Other non-thiol non-amide non-phenolic drugs.
It has been hypothesized that the incorporation of thiol drugs into the keratinocyte structure lead to changes in the antigenic conformation of DSG, with production of anti-DSG 1 and 3 antibodies responsible to immune acantholysis. Furthermore, it has been shown that thiol drugs could lead to general immune imbalance resulting in amplification of the acantholytic self-injury (Ruocco et al., 1993 ,Wolf et al., 1991 , Ong et al., 2000 , Ruocco, Pisani, de Angelis, & Lombardi, 1990 . Regarding phenol drugs, it has been assumed that pemphigus onset could be related to IL-1α and tumor necrosis factor-α from keratinocytes; cytokines involved in the regulation and synthesis of complement and proteases like plasminogen activator with consequent development of acantholysis (Goldberg, Modified from Kitajima (2003) Kashman, & Brenner, 1999; Pietkiewicz, Gornowicz-Porowska, BowszycDmochowska, & Dmochowski, 2015) . Recently, it has also been hypothesized the potential role of amides in the pathogenesis of pemphigus (Lo Schiavo, Sangiuliano, Puca, Brunetti, & Ruocco, 2009; Wolf et al., 1991) . Several mechanisms have been postulated in the pemphigus onset due to non-thiol and non-phenol drugs as overexpression of target antigens on keratinocyte membrane, hyperactivation of the immune system, increase of the local immune response and release of plasminogen activators by keratinocytes (Wolf et al., 1991) . Literature data showed increasing evidence of cases of pemphigus due to several systemic drugs penicillamine (Popadic, Skiljevic, & Medenica, 2009) , penicillin (Heymann, Chodick, Kramer, Green, & Shalev, 2007) , ampicillin (Hodak, Ben-Shetrit, Ingber, & Sandbank, 1990) , amoxicillin/clavulanic acid (Baroni, Russo, Faccenda, & Piccolo, 2012) , some cephalosporins (Baroni et al., 2009; Pellicano, Iannantuono, & Lomuto, 1993; Scardina, Conti, & Messina, 2004) , quinolones (Anadolu, Birol, Bostanci, & Boyvatt, 2002) , most nonsteroidal anti-inflammatory drugs (Durdu, Baba, & Seckin, 2011; Kanitakis, Souillet, Faure, & Claudy, 2001; Laing, Sheretz, & Flowers, 1988; Pompeova, 1981) , nifedipine (Ameen, Harman, & Black, 2000) , (Parfrey, Clement, Vandenburg, & Wright, 1980) . Penicillamine was the first drug described to cause pemphigus (Popadic et al., 2009 ) and have a similar chemical structure to captopril (Parfrey et al., 1980) . Each compound has a highly reactive negatively charged sulfhydryl group in a stable stereochemical relationship to a similarly negatively charged carbonyl group. As mentioned it has been theorized that the free sulfhydryl group in captopril contributes to causing skin disorders (Parfrey et al., 1980) . Since that time increasing evidence suggested a relationship between onset of pemphigus and treatment with ACE-I or angiotensin receptor blockers (enalapril, lisinopril, benazepril hydrochloride, fosinopril sodium, quinapril hydrochloride, and ramipril) (Brenner & Goldberg, 2011 , Ruocco & Sacerdoti, 1991 , Ruocco et al., 1993 ,Gavras & Gavras, 1983 , Pietkiewicz, Bowszyc-Dmochowska, & Dmochowski, 2011 , Parodi, Cozzani, Milesi, Drosera, & Rebora, 2002 , Adriano, Hamester, Nunes, & Di Giunta, 2011 , Goldberg et al., 2005 , Patterson & Davies, 2004 , Bae, Yun, Lee, Park, & Lee, 2008 , Bernard, Fayol, Delhoume, Catanzano, & Bonnetblanc, 1985 , Mallet, Cooper, & Thomas, 1989 , Smith, Taylor, Meyer, & Zone, 1993 , Mullins & Choudhury, 1994 , Thami, Kaur, & Kanwar, 2001 & Muller, 1994 , Bastiaens, Zwan, Verschueren, Stoof, & Nieboer, 1994 , Shelton, 1991 , Arnoux, Guiguen, & Verdier, 1987 , Katz, Hood, & Anhalt, 1987 , Ricci et al., 1986 , Saraceno, Citarella, Spallone, & Chimenti, 2008 . Recently, it has been reported a case of mucosal-dominant pemphigus vulgaris in a woman taking captopril during arterial hypertension (Gornowicz-Porowska, Dmochowski, . Furthermore, a retrospective study analyzed pemphigus onset in patients treated with ACE-I showing a strong correlation and that the most frequently used culprit drugs were ramipril and enalapril . A recent study analyzed a group of 62 hypertensive patients without skin diseases treated with ACE-I to verify the presence of serum circulating anti-antibodies showing that 33 (52.38%) patients presented autoantibodies directed to an antigen of the cytoplasm of the superficial epidermal keratinocytes (Cozzani et al., 2011) .
Here the present authors report three cases of pemphigus induced by ACE-I or angiotensin receptor blockers drug.
| CASE 1
A 78-year-old male patient with arterial hypertension and dyslipide- Framingham Heart Study, 60% of the population of sexagenarians develops arterial hypertension, and the percentage increases to 65% and 75%, respectively for men and women of 75 years of age (Chaudhry, Chavez, Gasowski, Grodzicki, & Messerli, 2012) . Therefore, the occurrence of cutaneous adverse events following antihypertensive therapy will tend to affect mainly middle-aged and elderly subjects with serious disease and it is necessary for the clinician to intervene promptly. These classes of drugs seem to be the most often reported antihypertensive pemphigus-associated drugs in both pemphigus vulgaris with molecules as captopril (Feng et al., 2011; Garcıa et al., 2016; Korman, Eyre, Zone, & Stanley, 1991) , fosinopril (Garcıa et al., 2016) enalapril (Patsatsi et al., 2009) , cilazapril (Parfrey et al., 1980) , quinapril (Ong et al., 2000) , benazepril (Goldberg, Shirazi, & Brenner, 2008) and Ramipril (Skandalis et al., 2012) , and in pemphigus foliaceus with molecules as captopril (Blanken, Doeglas, de Jong, Kardaun, & van Leeuwen, 1988; Christeler, Waeber, Brunner, & Delacrétaz, 1982; Goldberg et al., 2008) , enalapril (Bernard et al., 1985) , Ong et al., 2000) , cilazapril (Thami et al., 2001 ), lisinopril (Korman et al., 1991) , ramipril (Stavropoulos et al., 2003) . The first report on pemphigus induced by an antihypertensive (captopril) is dated 1980 (Goldberg et al., 2005) and from that date a large number of other antihypertensives has been reported to cause pemphigus (Brenner & Goldberg, 2011; Ruocco et al., 1993; Ruocco & Sacerdoti, 1991) . The antihypertensive therapy in the onset of pemphigus poses a serious problem as the knowledge about relation of these dermatoses and antihypertensives is inadequate not only among general practitioners, but also among dermatologists, who are not aware that recalcitrant or severe PV/PF, irresponsive to intensive treatment, may be caused by a harmful antihypertensive sustaining or triggering the disease. As many patients with drug-induced pemphigus have tissue-bound as well as serum autoantibodies to DSG1 and/or DSG3 (Bialy-Golan & Brenner, 1996; Korman et al., 1991) , the determination whether the disease is drug-induced or just drugexacerbated is troublesome. Although the mechanism by which these agents trigger and/or sustain autoimmunity in drug-induced pemphigus patients is still unknown, some theories propose a causative role of drug functional groups (Schmutz, Barbaud, & Trechot, 2002; Yamamoto et al., 2010) . Causal relations between PV/PF and drugs are based mainly and only on case reports and small-scale studies.
Drug-related pemphigus might be clinically divided into two groups (Ong et al., 2000) : a first group, in which the external factors play a major role in the development of the reaction and a second one, in which external factors play a secondary role. Our first case reported a pemphigus associated with ramipril use, an ACE-I with no thiol group.
Although pemphigus vulgaris is traditionally related to this case of adverse reaction, in our first case the patient developed pemphigus erythematosus, which is usually related to ACE-Is with a thiol group, such as captopril. ARBs are drugs used as alternative to ACE-I, especially when this kind of drugs shows some adverse effects. However, as reported in literature and in our case reports 2 and 3, ARBs may represent a possible trigger in generating pemphigus (Bae et al., 2008 ).
In our experience, the present authors recorded that this kind of drugs may be implicated in the genesis of both pemphigus vulgaris and (Ruocco, Satriano, & Guerrera, 1992) . In all case reports a systemic treatment with corticosteroid drugs (methylprednisolone) and the substitution of the suspected drug were sufficient to resolve the clinical case.
| CONCLUSIONS
Angiotensin's pathway inhibiting drugs are widely used substances in the treatment of primary and secondary hypertension, often associated with other molecules, such as diuretics, beta blockers, and vasodilators. Although sometimes it may be difficult to individuate the exact drug responsible for an adverse event, as the appearance of a bullous disease like pemphigus, the association between this kind of drugs and pemphigus is, although rare, present and the adverse reaction may present months or even years after the beginning of pharmacological treatment. When a drug induced bullous disease is probable, it is necessary to interrupt the suspected substance and to start a high dose treatment with corticosteroid drugs to resolve the clinical case in a short period of time considering that it could be life-threatening.
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